Related references
Note: Only part of the references are listed.The role of pseudophosphatases as signaling regulators
Shanta D. Hinton
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2019)
TPX2/Aurora kinase A signaling as a potential therapeutic target in genomically unstable cancer cells
Stephanie E. van Gijn et al.
ONCOGENE (2019)
Inhibitory Effect of CAPE and Kaempferol in Colon Cancer Cell LinesPossible Implications in New Therapeutic Strategies
Liviuta Budisan et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Biological Rationale for Targeting MEK/ERK Pathways in Anti-Cancer Therapy and to Potentiate Tumour Responses to Radiation
Francesco Marampon et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Autophagy-induced senescence is regulated by p38α signaling
Konstantin Slobodnyuk et al.
CELL DEATH & DISEASE (2019)
The Function of Non-Coding RNAs in Lung Cancer Tumorigenesis
Cornelia Braicu et al.
CANCERS (2019)
Role of Key Micronutrients from Nutrigenetic and Nutrigenomic Perspectives in Cancer Prevention
Alexandra Iulia Irimie et al.
MEDICINA-LITHUANIA (2019)
FGF5 promotes osteosarcoma cells proliferation via activating MAPK signaling pathway
Dunxin Han et al.
CANCER MANAGEMENT AND RESEARCH (2019)
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
Ryan J. Sullivan et al.
CANCER DISCOVERY (2018)
Kras and Tumor Immunity: Friend or Foe?
Jane Cullis et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2018)
Natural products with anti-aging potential: Affected targets and molecular mechanisms
Cristina-Sorina Catana et al.
BIOTECHNOLOGY ADVANCES (2018)
Oncogenic Signaling Pathways in The Cancer Genome Atlas
Francisco Sanchez-Vega et al.
CELL (2018)
PTEN is indispensable for cells to respond to MAPK inhibitors in myeloid leukemia
Jingliao Zhang et al.
CELLULAR SIGNALLING (2018)
Effects of PTEN Loss and Activated KRAS Overexpression on Mechanical Properties of Breast Epithelial Cells
Will Linthicum et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
NSC 95397 Suppresses Proliferation and Induces Apoptosis in Colon Cancer Cells through MKP-1 and the ERK1/2 Pathway
Navneet Kumar Dubey et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models
Anais Del Curatolo et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
EGFR-TKIs resistance via EGFR-independent signaling pathways
Qian Liu et al.
MOLECULAR CANCER (2018)
RAS-MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR-MEK Blockade
Bruno Bockorny et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers
Hiroshi Kotani et al.
ONCOGENE (2018)
Toosendanin, a natural product, inhibited TGF-1-induced epithelial-mesenchymal transition through ERK/Snail pathway
Weiwei Luo et al.
PHYTOTHERAPY RESEARCH (2018)
The Role of Autophagy in the Resistance to BRAF Inhibition in BRAF-Mutated Melanoma
Xiao Liu et al.
TARGETED ONCOLOGY (2018)
Keeping Tumors Out of the MAPK fitness Zone
David F. Stern
CANCER DISCOVERY (2018)
Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy
Feifei Liu et al.
ACTA PHARMACEUTICA SINICA B (2018)
Insights of Crosstalk between p53 Protein and the MKK3/MKK6/p38 MAPK Signaling Pathway in Cancer
Lorenzo Stramucci et al.
CANCERS (2018)
mTOR Cross-Talk in Cancer and Potential for Combination Therapy
Fabiana Conciatori et al.
CANCERS (2018)
Enterolactone modulates the ERK/NF-κB/Snail signaling pathway in triple-negative breast cancer cell line MDA-MB-231 to revert the TGF-β-induced epithelial-mesenchymal transition
Aniket Mali et al.
CANCER BIOLOGY & MEDICINE (2018)
Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer
Hiroki Sato et al.
CANCER SCIENCE (2018)
Multi-Scale Network Model Supported by Proteomics for Analysis of Combined Gemcitabine and Birinapant Effects in Pancreatic Cancer Cells
Xu Zhu et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2018)
Fruits as Prospective Reserves of bioactive Compounds: A Review
Marines Marli Gniech Karasawa et al.
NATURAL PRODUCTS AND BIOPROSPECTING (2018)
Resveratrol: A Double-Edged Sword in Health Benefits
Bahare Salehi et al.
BIOMEDICINES (2018)
Coumestrol Inhibits Proliferation and Migration of Prostate Cancer Cells by Regulating AKT, ERK1/2, and JNK MAPK Cell Signaling Cascades
Whasun Lim et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2017)
Inhibitory Effects of Quercetin on Progression of Human Choriocarcinoma Cells Are Mediated Through PI3K/AKT and MAPK Signal Transduction Cascades
Whasun Lim et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2017)
P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition
Ahmad Najem et al.
EUROPEAN JOURNAL OF CANCER (2017)
Isotrifoliol inhibits pro-inflammatory mediators by suppression of TLR/NF-κB and TLR/MAPK signaling in LPS-induced RAW264.7 cells
Hua Li et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2017)
Dietary Intervention by Phytochemicals and Their Role in Modulating Coding and Non-Coding Genes in Cancer
Liviuta Budisan et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
5,6,7,3′,4′,5′-Hexamethoxyflavone inhibits growth of triple-negative breast cancer cells via suppression of MAPK and Akt signaling pathways and arresting cell cycle
Natasha Borah et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2017)
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
Michael A. Davies et al.
LANCET ONCOLOGY (2017)
Linc-RoR promotes MAPK/ERK signaling and confers estrogen-independent growth of breast cancer
Wan-xin Peng et al.
MOLECULAR CANCER (2017)
Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)
Ursula A. Germann et al.
MOLECULAR CANCER THERAPEUTICS (2017)
PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas
Hezhe Lu et al.
NATURE (2017)
MEK inhibitor, PD98059, promotes breast cancer cell migration by inducing β-catenin nuclear accumulation
Ying Zhao et al.
ONCOLOGY REPORTS (2017)
Nutrigenomics in cancer: Revisiting the effects of natural compounds
Cornelia Braicu et al.
SEMINARS IN CANCER BIOLOGY (2017)
Escin induces caspase-dependent apoptosis and autophagy through the ROS/p38 MAPK signalling pathway in human osteosarcoma cells in vitro and in vivo
Jian Zhu et al.
CELL DEATH & DISEASE (2017)
The new era of nanotechnology, an alternative to change cancer treatment
Ancuta Jurj et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2017)
Genistein inhibits the growth and regulates the migration and invasion abilities of melanoma cells via the FAK/paxillin and MAPK pathways
Shuna Cui et al.
ONCOTARGET (2017)
EGFR signaling pathways are wired differently in normal 184A1L5 human mammary epithelial and MDA-MB-231 breast cancer cells
Zachary Speth et al.
JOURNAL OF CELL COMMUNICATION AND SIGNALING (2017)
PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer
Michele Milella et al.
SCIENTIFIC REPORTS (2017)
Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors
Concetta Di Mauro et al.
SCIENTIFIC REPORTS (2017)
The good-cop bad-cop TGF-beta role in breast cancer modulated by non-coding RNAs
Diana Gulei et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2017)
A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor
Johanna C. Bendell et al.
BRITISH JOURNAL OF CANCER (2017)
A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer
Amita Patnaik et al.
CLINICAL CANCER RESEARCH (2016)
Expression profile of COL2A1 and the pseudogene SLC6A10P predicts tumor recurrence in high-grade serous ovarian cancer
Mahrukh K. Ganapathi et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Monitoring Ras Interactions with the Nucleotide Exchange Factor Son of Sevenless (Sos) Using Site-specific NMR Reporter Signals and Intrinsic Fluorescence
Uybach Vo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Inhibition of Survival Pathways MAPK and NF-kB Triggers Apoptosis in Pancreatic Ductal Adenocarcinoma Cells via Suppression of Autophagy
Daniela Laura Papademetrio et al.
TARGETED ONCOLOGY (2016)
Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway
Tingting Wang et al.
ONCOTARGET (2016)
Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer
C. A. Carter et al.
ANNALS OF ONCOLOGY (2016)
IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras-Mutant Lung Cancer
Mauricio S. Caetano et al.
CANCER RESEARCH (2016)
Apigenin Reduces Survival of Choriocarcinoma Cells by Inducing Apoptosis via the PI3K/AKT and ERK1/2 MAPK Pathways
Whasun Lim et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2016)
Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
David Planchard et al.
LANCET ONCOLOGY (2016)
Caffeic acid phenethyl ester activates pro-apoptotic and epithelial-mesenchymal transition-related genes in ovarian cancer cells A2780 and A2780cis
Claudia Gherman et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2016)
HER Specific TKIs Exert Their Antineoplastic Effects on Breast Cancer Cell Lines through the Involvement of STAT5 and JNK
Daphne Gschwantler-Kaulich et al.
PLOS ONE (2016)
Overcoming MITF-conferred drug resistance through dual AURKA/MAPK targeting in human melanoma cells
G. Pathria et al.
CELL DEATH & DISEASE (2016)
JNK1/2 expression and modulation of STAT3 signaling in oral cancer
Ioannis Gkouveris et al.
ONCOLOGY LETTERS (2016)
Current Insights into Long Non-Coding RNAs in Renal Cell Carcinoma
Maximilian Seles et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Metastatic Melanoma - A Review of Current and Future Treatment Options
Emanual Maverakis et al.
ACTA DERMATO-VENEREOLOGICA (2015)
Novel technologies for oral squamous carcinoma biomarkers in diagnostics and prognostics
Alexandra Iulia Irimie et al.
ACTA ODONTOLOGICA SCANDINAVICA (2015)
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)
G. R. Blumenschein et al.
ANNALS OF ONCOLOGY (2015)
PIP2 and PIP3 interact with N-terminus region of TRPM4 channel
Kristyna Bousova et al.
BIOPHYSICAL CHEMISTRY (2015)
Regulation of RAF protein kinases in ERK signalling
Hugo Lavoie et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2015)
Phytochemicals modulate carcinogenic signaling pathways in breast and hormone-related cancers
Roxana Cojocneanu Petric et al.
ONCOTARGETS AND THERAPY (2015)
The nuclear translocation of ERK1/2 as an anticancer target
Alexander Plotnikov et al.
NATURE COMMUNICATIONS (2015)
Mutant HRAS as novel target for MEK and mTOR inhibitors
Michael K. Kiessling et al.
ONCOTARGET (2015)
Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma
Anthony W. Tolcher et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Teriflunomide, an immunomodulatory drug, exerts anticancer activity in triple negative breast cancer cells
Ou Huang et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2015)
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
Holly E. Barker et al.
NATURE REVIEWS CANCER (2015)
Upregulation of MAPK/Erk and PI3K/Akt pathways in ulcerative colitis-associated colon cancer
Shruti Setia et al.
BIOMEDICINE & PHARMACOTHERAPY (2014)
The MAPK Pathway Across Different Malignancies: A New Perspective
Mauricio Burotto et al.
CANCER (2014)
NCRNA Combined Therapy as Future Treatment Option for Cancer
Cornelia Braicu et al.
CURRENT PHARMACEUTICAL DESIGN (2014)
Statins and breast cancer prognosis: evidence and opportunities
Thomas P. Ahern et al.
LANCET ONCOLOGY (2014)
A role for p38 MAPK in head and neck cancer cell growth and tumor-induced angiogenesis and lymphangiogenesis
Kantima Leelahavanichkul et al.
MOLECULAR ONCOLOGY (2014)
Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway
Jiri Polivka et al.
PHARMACOLOGY & THERAPEUTICS (2014)
Dimerization of the kinase ARAF promotes MAPK pathway activation and cell migration
Juliane Mooz et al.
SCIENCE SIGNALING (2014)
Complex interactions between the components of the PI3K/AKT/mTOR pathway, and with components of MAPK, JAK/STAT and Notch-1 pathways, indicate their involvement in meningioma development
Elias A. El-Habr et al.
VIRCHOWS ARCHIV (2014)
p38α MAPK pathway: A key factor in colorectal cancer therapy and chemoresistance
Valentina Grossi et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
p38MAPK Plays a Crucial Role in Stromal-Mediated Tumorigenesis
Elise Alspach et al.
CANCER DISCOVERY (2014)
The Immune Microenvironment Confers Resistance to MAPK Pathway Inhibitors through Macrophage-Derived TNFα
Michael P. Smith et al.
CANCER DISCOVERY (2014)
Another review on triple negative breast cancer. Are we on the right way towards the exit from the labyrinth?
Roxana Chiorean et al.
BREAST (2013)
Oncogenes and inflammation rewire host energy metabolism in the tumor microenvironment RAS and NFκB target stromal MCT4
Ubaldo E. Martinez-Outschoorn et al.
CELL CYCLE (2013)
Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors
Karen E. Sheppard et al.
EUROPEAN JOURNAL OF CANCER (2013)
p53siRNA therapy reduces cell proliferation, migration and induces apoptosis in triple negative breast cancer cells
Cornelia Braicu et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2013)
Microenvironmental regulation of tumor progression and metastasis
Daniela F. Quail et al.
NATURE MEDICINE (2013)
BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition
Rizwan Haq et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer
Philip A. Philip et al.
CANCER (2012)
MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors
Alexa B. Turke et al.
CANCER RESEARCH (2012)
Pten Loss and RAS/MAPK Activation Cooperate to Promote EMT and Metastasis Initiated from Prostate Cancer Stem/Progenitor Cells
David J. Mulholland et al.
CANCER RESEARCH (2012)
Inside-out, outside-in, and inside-outside-in: G protein signaling in integrin-mediated cell adhesion, spreading, and retraction
Bo Shen et al.
CURRENT OPINION IN CELL BIOLOGY (2012)
Ras family of small GTPases in immunity and inflammation
Derek S. Johnson et al.
CURRENT OPINION IN PHARMACOLOGY (2012)
Sorafenib for advanced-stage hepatocellular carcinoma
Ciprian Tomuleasa et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2012)
Early transcriptional pattern of angiogenesis induced by EGCG treatment in cervical tumour cells
Oana Tudoran et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2012)
Survival in BRAF V600-Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey A. Sosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Approaches to Data Analyses of Clinical Trials
Curt D. Furberg et al.
PROGRESS IN CARDIOVASCULAR DISEASES (2012)
TGF-β-induced epithelial-mesenchymal transition: A link between cancer and inflammation
Jonas Fuxe et al.
SEMINARS IN CANCER BIOLOGY (2012)
The MAPK cascades: Signaling components, nuclear roles and mechanisms of nuclear translocation
Alexander Plotnikov et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2011)
Opportunities and Challenges in the Development of Experimental Drug Combinations for Cancer
Rachel W. Humphrey et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases
Marie Cargnello et al.
MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS (2011)
Resistance to MEK Inhibitors: Should We Co-Target Upstream?
Poulikos I. Poulikakos et al.
SCIENCE SIGNALING (2011)
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
Michelle C. Mendoza et al.
TRENDS IN BIOCHEMICAL SCIENCES (2011)
Partners in crime: the TGFβ and MAPK pathways in cancer progression
Douglas A. Chapnick et al.
CELL AND BIOSCIENCE (2011)
HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment
Britta Weigelt et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Cell Signaling by Receptor Tyrosine Kinases
Mark A. Lemmon et al.
CELL (2010)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos et al.
NATURE (2010)
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Georgia Hatzivassiliou et al.
NATURE (2010)
Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements
Shivanni Kummar et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
Eric W. Joseph et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers
Susan Wee et al.
CANCER RESEARCH (2009)
C-Raf Is Associated with Disease Progression and Cell Proliferation in a Subset of Melanomas
Lucia B. Jilaveanu et al.
CLINICAL CANCER RESEARCH (2009)
Spred1 and TESK1 - Two new interaction partners of the kinase MARKK/TAO1 that link the microtubule and actin cytoskeleton
Cindy Johne et al.
MOLECULAR BIOLOGY OF THE CELL (2008)
Mechanisms of disease: epithelial-mesenchymal transition - does cellular plasticity fuel neoplastic progression?
Eva A. Turley et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2008)
MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300
NL Sang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Rheb is in a high activation state and inhibits B-Raf kinase in mammalian cells
E Im et al.
ONCOGENE (2002)
Fibronectin fragments and blocking antibodies to α2β1 and α5β1 integrins stimulate mitogen-activated protein kinase signaling and increase collagenase 3 (matrix metalloproteinase 13) production by human articular chondrocytes
CB Forsyth et al.
ARTHRITIS AND RHEUMATISM (2002)
Share Paper
